Pro zobrazení tohoto obsahu je třeba být přihlášen.
Categories for Uncategorized
First-line carboplatin and pemetrexed (CP) with or without pembrolizumab (pembro) for advanced nonsquamous NSCLC: Updated results of KEYNOTE-021 cohort G
29 septembra, 2020 8:31 pmMeeting: 2017 ASCO Annual Meeting Track: Lung Cancer – Non-small Cell Metastatic Abstract number: 9094 Citation: J...
Nivolumab (N) plus ipilimumab (I) as first-line (1L) treatment for advanced (adv) NSCLC: 2-yr OS and long-term outcomes from CheckMate 012
29 septembra, 2020 8:31 pmMeeting: 2017 ASCO Annual Meeting Track: Lung Cancer – Non-small Cell Metastatic Abstract number: 9093 Citation: J...
Response to salvage chemotherapy following exposure to immune checkpoint inhibitors in patients with non-small cell lung cancer
29 septembra, 2020 8:31 pmMeeting: 2017 ASCO Annual Meeting Track: Lung Cancer – Non-small Cell Metastatic Abstract number: 9084 Citation: J...
Efficacy, safety, and biomarker results of trastuzumab emtansine (T-DM1) in patients (pts) with previously treated HER2-overexpressing locally advanced or metastatic non-small cell lung cancer (mNSCLC)
29 septembra, 2020 8:31 pmMeeting: 2017 ASCO Annual Meeting Track: Lung Cancer – Non-small Cell Metastatic Abstract number: 8509 Citation: J...
Education Session Reviews Current Management of Early-Stage NSCLC, Offers Glimpse of Future Advances
29 septembra, 2020 8:31 pmJune 3, 2017 Approximately 15% of all patients with non–small cell lung cancer (NSCLC) present with disease in early...
KARCINÓM PĽÚC NA ASCO 2017
29 septembra, 2020 8:31 pmÚvod Konferencia ASCO 2017 (v ďalšom texte iba ASCO) priniesla tento rok v oblasti karcinómu pľúc celý rad nových poznatkov a pre mňa...
A randomized phase II cross-over study of abiraterone + prednisone (ABI) vs enzalutamide (ENZ) for patients (pts) with metastatic, castration-resistant prostate cancer (mCRPC)
29 septembra, 2020 8:31 pmMeeting: 2017 ASCO Annual Meeting Track: Genitourinary (Prostate) Cancer Abstract number: 5002 Citation: J Clin Oncol 35,...
Biomarker findings and mature clinical results from KEYNOTE-052: First-line pembrolizumab (pembro) in cisplatin-ineligible advanced urothelial cancer (UC)
29 septembra, 2020 8:31 pmMeeting: 2017 ASCO Annual Meeting Track: Genitourinary (Nonprostate) Cancer Abstract number: 5502 Citation: J Clin Oncol 35,...
Comprehensive molecular characterization and analysis of muscle-invasive urothelial carcinomas
29 septembra, 2020 8:31 pmMeeting: 2017 ASCO Annual Meeting Track: Genitourinary (Nonprostate) Cancer Abstract number: 4500 Citation: J Clin Oncol 35,...
Planned survival analysis from KEYNOTE-045: Phase 3, open-label study of pembrolizumab (pembro) versus paclitaxel, docetaxel, or vinflunine in recurrent, advanced urothelial cancer (UC)
29 septembra, 2020 8:30 pmMeeting: 2017 ASCO Annual Meeting Track: Genitourinary (Nonprostate) Cancer Abstract number: 4501 Citation: J Clin Oncol 35,...